Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX)

Q: What does CUSIP 45720N103 represent in this 13F holders report?

CUSIP 45720N103 is the security identifier for INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share in Q1 2026?

27 institutional investors reported INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 45720N103

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 14,560,641
Total 13F shares: 1,033,287
Share change: -46,487
Total reported value: $69,467,396
Price per share: $67.23
Number of holders: 27
Value change: -$3,442,361
Number of buys: 13
Number of sells: 9

Quarterly Holders Quick Answers

What is CUSIP 45720N103?
CUSIP 45720N103 identifies INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 45720N103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of INBX - Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PERCEPTIVE ADVISORS LLC	13F	Company	10%	1,452,707	$114,763,853	—	31 Dec 2025	13F
VIKING GLOBAL INVESTORS LP	13F 13D/G 3/4/5	Company · 10%+ Owner	10% from 13D/G	1,437,705	$113,578,695	—	31 Dec 2025	13F 13D/G 3/4/5
MORGAN STANLEY	13F 13D/G	Company	7.9% from 13D/G	1,167,728	$92,250,538	—	31 Dec 2025	13F 13D/G
Sanofi	13F	Company	8%	1,157,926	$91,476,154	—	31 Dec 2025	13F
HighTower Advisors, LLC	13F	Company	6%	870,507	$68,770,053	—	31 Dec 2025	13F
BlackRock, Inc.	13F 13D/G	Company	5.3% from 13D/G	777,383	$61,413,257	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	4.3%	623,084	$49,223,636	—	31 Dec 2025	13F
Sofinnova Investments, Inc.	13F	Company	3.1%	454,657	$35,917,903	—	31 Dec 2025	13F
Capital Research Global Investors	13F	Company	2.9%	421,575	$33,304,425	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	2.6%	374,961	$29,621,919	—	31 Dec 2025	13F
Caligan Partners LP	13F	Company	2.2%	323,565	$25,561,635	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	2%	297,116	$23,472,164	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.9%	275,917	$21,797,443	—	31 Dec 2025	13F
PFM Health Sciences, LP	13F	Company	1.8%	265,517	$20,975,843	—	31 Dec 2025	13F
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	13F	Company	1.8%	264,000	$20,856,000	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.6%	226,009	$17,858,743	—	31 Dec 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	1.5%	214,725	$16,963,275	—	31 Dec 2025	13F
Mark P. Lappe	3/4/5 13D/G	Chief Executive Officer, Director · Mark Lappe	6.4% from 13D/G	1,225,413 mixed-class rows	$15,852,324	—	12 Sep 2024	3/4/5 13D/G
Jon Faiz Kayyem	3/4/5 13D/G	Director	7.9% from 13D/G	1,074,046 mixed-class rows	$15,030,087	—	28 May 2025	3/4/5 13D/G
Woodline Partners LP	13F	Company	0.96%	139,479	$11,018,841	—	31 Dec 2025	13F
NORGES BANK	13F	Company	0.92%	133,300	$10,530,700	—	31 Dec 2025	13F
D. E. Shaw & Co., Inc.	13F	Company	0.84%	122,101	$9,645,979	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.77%	112,396	$8,879,284	—	31 Dec 2025	13F
CDC Financial, Inc.	13F	Company	0.76%	110,810	$8,753,990	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.69%	100,617	$7,948,743	—	31 Dec 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.63%	92,009	$7,268,711	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.61%	88,509	$6,992,211	—	31 Dec 2025	13F
SummitTX Capital, L.P.	13F	Company	0.57%	82,885	$6,547,915	—	31 Dec 2025	13F
Brendan P. Eckelman	3/4/5	Chief Scientific Officer	— mixed-class rows	648,888 mixed-class rows	$6,127,372	—	29 May 2024	3/4/5
UBS Group AG	13F	Company	0.51%	73,699	$5,822,221	—	31 Dec 2025	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.49%	71,488	$5,647,552	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.47%	69,119	$5,460,401	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0.38%	55,759	$4,404,961	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.36%	52,600	$4,155,400	—	31 Dec 2025	13F
FMR LLC	13F	Company	0.32%	46,269	$3,655,220	—	31 Dec 2025	13F
Laird Norton Wetherby Trust Company, LLC	13F	Company	0.28%	40,382	$3,190,178	—	31 Dec 2025	13F
Douglas G. Forsyth	3/4/5	Director	— mixed-class rows	239,564 mixed-class rows	$3,159,615	—	28 May 2025	3/4/5
ArrowMark Colorado Holdings LLC	13F	Company	0.24%	35,176	$2,778,904	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.23%	33,019	$2,608,501	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	0.2%	29,310	$2,315,490	—	31 Dec 2025	13F
FRANKLIN RESOURCES INC	13F	Company	0.2%	29,308	$2,315,332	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.19%	28,393	$2,243,047	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.19%	27,341	$2,159,939	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.18%	26,900	$2,125,100	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.18%	26,748	$2,113,092	—	31 Dec 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.17%	25,390	$2,005,000	—	31 Dec 2025	13F
Soleus Capital Management, L.P.	13F	Company	0.17%	25,000	$1,975,000	—	31 Dec 2025	13F
Empirical Financial Services, LLC d.b.a. Empirical Wealth Management	13F	Company	0.16%	22,883	$1,807,757	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.15%	21,879	$1,728,441	—	31 Dec 2025	13F
Russell Investments Group, Ltd.	13F	Company	0.14%	20,778	$1,641,462	—	31 Dec 2025	13F

Institutional Holders of Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) as of Q1 2026

As of 31 Mar 2026, Inhibrx Biosciences, Inc. - Common Stock, par value $0.0001 per share (INBX) was held by 27 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,033,287 shares. The largest 10 holders included HighTower Advisors, LLC, UBS Group AG, Bank of New York Mellon Corp, Empirical Financial Services, LLC d.b.a. Empirical Wealth Management, Nuveen, LLC, Ethic Inc., PROFUND ADVISORS LLC, PSP Research LLC, Janney Montgomery Scott LLC, and NBC SECURITIES, INC.. This page lists 27 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

138

Q1 2026 holders

Holder diff

-111

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.